US FDA Approval of Pediatric Artificial Intelligence and Machine Learning-Enabled Medical Devices [0.03%]
美国FDA批准儿科人工智能和机器学习辅助医疗设备审批
Ryan C L Brewster,Matthew Nagy,Susmitha Wunnava et al.
Ryan C L Brewster et al.
Rachael W Taylor,Jillian J Haszard,Bradley Brosnan
Rachael W Taylor
Ross D Neville
Ross D Neville
Conditional and Unconditional Social Transfers, Early-Life Nutrition, and Child Growth: A Randomized Clinical Trial [0.03%]
有条件和无条件的社会转移支付、早期营养与儿童生长关系的随机临床试验
Jordyn T Wallenborn,Souliviengkham Sonephet,Somphou Sayasone et al.
Jordyn T Wallenborn et al.
Importance: Rates of exclusive breastfeeding are declining despite the numerous benefits to mothers and their children. Objective: To a...
Jeromie Ballreich,Ilina C Odouard,Mariana P Socal
Jeromie Ballreich
Adverse Obstetric Outcomes in Pregnancies With Major Fetal Congenital Heart Defects [0.03%]
重大胎儿先天性心脏病的不良产科结局
Gitte Hedermann,Paula L Hedley,Kasper Gadsbøll et al.
Gitte Hedermann et al.
Importance: Understanding the risk profile of obstetric complications in pregnancies with fetal major congenital heart defects (MCHDs) is crucial for obstetric counseling and care. ...
Qingwei Chen,Taotao Ru,Guofu Zhou
Qingwei Chen
Caroline Fitzpatrick,Annie Lemieux,Gabrielle Garon-Carrier
Caroline Fitzpatrick
External Validation of Brief Resolved Unexplained Events Prediction Rules for Serious Underlying Diagnosis [0.03%]
简化的不明原因事件预测严重潜在疾病的模型的外部验证研究
Nassr Nama,Ye Shen,Jeffrey N Bone et al.
Nassr Nama et al.
Importance: The American Academy of Pediatrics (AAP) higher-risk criteria for brief resolved unexplained events (BRUE) have a low positive predictive value (4.8%) and misclassify most infants as higher risk (>90%). New BR...
Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024 [0.03%]
2023至2024年度呼肠病毒疾病负担及尼塞维马b型单克隆抗体在婴幼儿中的疗效分析
Heidi L Moline,Ariana P Toepfer,Ayzsa Tannis et al.
Heidi L Moline et al.
Importance: During the 2023-2024 respiratory syncytial virus (RSV) season in the United States, 2 new RSV prevention products were recommended to protect infants in their first RSV season: nirsevimab and Pfizer's maternal...